Home > Boards > US Listed > Biotechs > Cytokinetics, Inc. (CYTK)

https://ih.advfn.com/p.php?pid=nmona&article=76140123http://ih.advfn.com/p.php?pid=nmona&amp

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
north40000 Member Profile
Member Level 
Followed By 195
Posts 16,200
Boards Moderated 0
Alias Born 01/19/06
160x600 placeholder
Cytokinetics to Host Virtual Investor & Analyst Day on July 15, 2020 GlobeNewswire Inc. - 7/1/2020 4:00:10 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/23/2020 5:00:57 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/22/2020 5:44:10 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/17/2020 6:08:43 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/15/2020 5:58:39 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/12/2020 6:32:46 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/12/2020 6:32:05 PM
Cytokinetics to Participate In Upcoming Investor Conferences GlobeNewswire Inc. - 6/8/2020 4:00:10 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/29/2020 7:45:44 PM
Securities Registration: Employee Benefit Plan (s-8) Edgar (US Regulatory) - 5/29/2020 4:09:10 PM
Cytokinetics and The ALS Association Renew Partnership to Advance the Fight Against ALS GlobeNewswire Inc. - 5/27/2020 7:30:10 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/20/2020 5:05:01 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/20/2020 5:04:50 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/18/2020 7:38:07 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/14/2020 4:47:46 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/14/2020 4:47:46 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/14/2020 4:47:29 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/14/2020 4:47:23 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/14/2020 4:46:46 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/14/2020 4:46:42 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/14/2020 4:46:21 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/14/2020 4:46:20 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/14/2020 4:01:20 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/12/2020 4:22:59 PM
Cytokinetics Shares Jump After FDA Fast Track Designation for Omecamtiv Mecarbil Dow Jones News - 5/11/2020 10:44:00 AM
north40000 Member Level  Tuesday, 11/21/17 09:06:42 AM
Re: Sugarshaker post# 1473
Post # of 1491 
https://ih.advfn.com/p.php?pid=nmona&article=76140123

http://ih.advfn.com/p.php?pid=nmona&article=76140679

Wife went to work, now I can post a link or 2, fwiw + some text from PR:


Cytokinetics Announces Negative Results From VITALITY-ALS

Today : Tuesday 21 November 2017




Cytokinetics, Incorporated (Nasdaq:CYTK) today announced that VITALITY-ALS (Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices after Treatment for a Year in ALS), the international Phase 3 clinical trial of tirasemtiv in patients with amyotrophic lateral sclerosis (ALS), did not meet the primary endpoint of change from baseline in slow vital capacity (SVC) which was evaluated at 24 weeks following randomization or any of the secondary endpoints in the trial which were evaluated at 48 weeks.

No new safety or tolerability findings related to tirasemtiv were identified in VITALITY-ALS. Serious adverse events were similar between patients who received tirasemtiv or placebo but more patients discontinued double-blind treatment on tirasemtiv than on placebo primarily due to non-serious adverse events related to tolerability. The decline in SVC from baseline to 24 weeks was smaller in patients who received any dose of tirasemtiv in VITALITY-ALS compared to the decline in patients receiving placebo. The largest differences from placebo were observed in patients randomized to the mid- and high-dose groups of tirasemtiv who could tolerate and remain on their target dose, although those differences were not statistically significant.

“While we are deeply disappointed by the results of VITALITY-ALS, we remain committed to people with ALS who are fighting this devastating disease and who need new therapies to slow the decline of respiratory function and muscle strength that are key hallmarks of disease progression,” said Robert I. Blum, Cytokinetics’ President and CEO. “We have decided to suspend the development of tirasemtiv. While we believe that VITALITY-ALS demonstrated pharmacologic activity for the mechanism of action, we also believe that limitations of tirasemtiv may be addressed with our next-generation fast skeletal muscle activator, CK-2127107. Based on previous Phase 1 clinical studies, we believe CK-2127107 will be better tolerated and potentially more effective than tirasemtiv in patients with ALS and look forward to Phase 2 trial results in 2018. We are grateful to the trial investigators, site personnel, patients and caregivers who participated in VITALITY-ALS.”

The results of VITALITY-ALS will be presented on December 8, 2017 at the 27th Annual International ALS/MND Symposium in Boston, MA by Jeremy Shefner, M.D., Ph.D., Lead Investigator of VITALITY-ALS, Professor and Chair of Neurology at Barrow Neurological Institute, and Professor and Executive Chair of Neurology at University of Arizona, Phoenix.

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist